Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
38.6M
-
Shares change
-
-2.04M
-
Total reported value, excl. options
-
$95.8M
-
Value change
-
-$4.38M
-
Number of buys
-
63
-
Number of sells
-
-42
-
Price
-
$2.48
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2025
123 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q2 2025.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.6M shares
of 56.1M outstanding shares and own 68.86% of the company stock.
Largest 10 shareholders include T. Rowe Price Investment Management, Inc. (10.5M shares), Vestal Point Capital, LP (5.6M shares), NEA Management Company, LLC (4.45M shares), Bellevue Group AG (2.73M shares), VANGUARD GROUP INC (2.1M shares), TANG CAPITAL MANAGEMENT LLC (2.07M shares), BlackRock, Inc. (1.09M shares), Siren, L.L.C. (1.05M shares), MILLENNIUM MANAGEMENT LLC (945K shares), and MARSHALL WACE, LLP (738K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.